{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:01:14Z","timestamp":1790802074157,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente"],"award-info":[{"award-number":["Ricerca Corrente"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["Alpe-d\\u2019HuZes\/KWF-fund NKI-2013-6249"],"award-info":[{"award-number":["Alpe-d\\u2019HuZes\/KWF-fund NKI-2013-6249"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon 2020","doi-asserted-by":"publisher","award":["668353"],"award-info":[{"award-number":["668353"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.phrs.2026.108451","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:12:17Z","timestamp":1789139537000},"page":"108451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["DPYD c.85\u202fT\u202f&gt;\u202fC, DPYD c.496\u202fA&gt;G, and DPYD c.2194\u202fG&gt;A and severe toxicity to fluoropyrimidines in PREPARE and Alpe-DPD trials. An original study and meta-analysis"],"prefix":"10.1016","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4948-8767","authenticated-orcid":false,"given":"Elena","family":"De Mattia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Polesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike","family":"van der Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Bohringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Gambron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Perfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Roncato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Canil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Posocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Cats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Spina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse J.","family":"Swen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7517-7490","authenticated-orcid":false,"given":"Erika","family":"Cecchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.108451_bib1","unstructured":"Food and Drug Administration Labels. Available from: https:\/\/www.curetoday.com\/view\/breaking-down-the-fda-labeling-update-of-xeloda-and-5-fu-in-cancer-care. Access Date: May 18, 2026."},{"key":"10.1016\/j.phrs.2026.108451_bib2","unstructured":"EMA. EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. European Medicines Agency. Published April 30, 2020. Available from: https:\/\/www.ema.europa.eu\/en\/news\/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-flucytosine. Access Date: May 18, 2026."},{"issue":"2","key":"10.1016\/j.phrs.2026.108451_bib3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2026.108451_bib4","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41431-019-0540-0","article-title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines","volume":"28","author":"Lunenburg","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"issue":"10","key":"10.1016\/j.phrs.2026.108451_bib5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jmoldx.2024.05.015","volume":"26","author":"Pratt","year":"2024","journal-title":"J. Mol. Diagn."},{"issue":"11","key":"10.1016\/j.phrs.2026.108451_bib6","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","volume":"19","author":"Henricks","year":"2018","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.phrs.2026.108451_bib7","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/ijc.29654","article-title":"Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines","volume":"137","author":"Toffoli","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2026.108451_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106949","article-title":"Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study","volume":"197","author":"Fragoulakis","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.phrs.2026.108451_bib9","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.ajhg.2019.04.017","article-title":"Estimating the effectiveness of DPYD genotyping in italian individuals suffering from cancer based on the cost of chemotherapy-induced toxicity","volume":"104","author":"Fragoulakis","year":"2019","journal-title":"Am. J. Hum. Genet."},{"issue":"12","key":"10.1016\/j.phrs.2026.108451_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.49441","article-title":"Clinical benefits and utility of pretherapeutic DPYD and UGT1A1 testing in gastrointestinal cancer: a secondary analysis of the prepare randomized clinical trial","volume":"7","author":"Roncato","year":"2024","journal-title":"JAMA Netw. Open."},{"issue":"4","key":"10.1016\/j.phrs.2026.108451_bib11","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/cpt.1257","article-title":"The genotype for DPYD risk variants in patients with colorectal cancer and the related toxicity management costs in clinical practice","volume":"105","author":"Toffoli","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2026.108451_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1199462","article-title":"Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: lessons learned on the path to implementation","volume":"14","author":"Bignucolo","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108451_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101197","article-title":"Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe","volume":"8","author":"de With","year":"2023","journal-title":"ESMO Open."},{"issue":"3","key":"10.1016\/j.phrs.2026.108451_bib14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.31083\/j.jmcm.2018.03.003","article-title":"DPYD gene activity score predicts dose-limiting toxicity in fluoropyrimidine-treated colorectal cancer patients","volume":"1","author":"Dalle Fratte","year":"2018","journal-title":"J. Mol. Clin. Med."},{"issue":"8","key":"10.1016\/j.phrs.2026.108451_bib15","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/bcp.15715","article-title":"Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: What are the explanatory factors?","volume":"89","author":"Arrive","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108451_bib16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/cpt.2608","article-title":"Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study","volume":"112","author":"de With","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2026.108451_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115483","article-title":"Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study","volume":"224","author":"Knikman","year":"2025","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.phrs.2026.108451_bib18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2217\/pgs-2022-0135","article-title":"DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand?","volume":"24","author":"Lesnjakovic","year":"2023","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.phrs.2026.108451_bib19","first-page":"1603","article-title":"Ethnic diversity of DPD activity and the DPYD gene: review of the literature","volume":"14","author":"White","year":"2021","journal-title":"Pharmgenomics Pers. Med."},{"issue":"4","key":"10.1016\/j.phrs.2026.108451_bib20","first-page":"320","article-title":"Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction","volume":"16","author":"Gentile","year":"2016","journal-title":"Pharm. J."},{"issue":"8","key":"10.1016\/j.phrs.2026.108451_bib21","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1111\/bcp.14742","article-title":"Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicity","volume":"87","author":"Hamzic","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108451_bib22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00280-022-04491-7","article-title":"Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype","volume":"91","author":"Medwid","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"10374","key":"10.1016\/j.phrs.2026.108451_bib23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","article-title":"A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study","volume":"401","author":"Swen","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.phrs.2026.108451_bib24","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.ejca.2014.04.030","article-title":"Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey","volume":"50","author":"Paoletti","year":"2014","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108451_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13073-024-01354-z","article-title":"Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD","volume":"16","author":"Knikman","year":"2024","journal-title":"Genome Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108451_bib26","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1515\/cclm-2025-0949","article-title":"Impact of renal and hepatic function on dihydropyrimidine dehydrogenase phenotype assessed by enzyme activity in peripheral blood mononuclear cells and uracilemia","volume":"64","author":"Contu","year":"2026","journal-title":"Clin. Chem. Lab. Med."},{"issue":"5","key":"10.1016\/j.phrs.2026.108451_bib27","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41416-023-02517-2","article-title":"Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis","volume":"130","author":"Le Teuff","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2026.108451_bib28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.0.CO;2-P","article-title":"Meta-analysis: formulating, evaluating, combining, and reporting","volume":"18","author":"Normand","year":"1999","journal-title":"Stat. Med."},{"issue":"10","key":"10.1016\/j.phrs.2026.108451_bib29","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J. Clin. Epidemiol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108451_bib30","doi-asserted-by":"crossref","first-page":"9831","DOI":"10.3390\/cimb46090584","article-title":"Dihydropyrimidine Dehydrogenase Polymorphism c.2194G>A Screening Is a Useful Tool for Decreasing Gastrointestinal and Hematological Adverse Drug Reaction Risk in Fluoropyrimidine-Treated Patients","volume":"46","author":"Ardizzone","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108451_bib31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/djaf357","article-title":"A predictive model for life-threatening fluoropyrimidine toxicity based on DPYD sequencing in colorectal cancer","volume":"118","author":"Boige","year":"2026","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.phrs.2026.108451_bib32","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamaoncol.2015.5392","article-title":"DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial","volume":"2","author":"Boige","year":"2016","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108451_bib33","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1111\/bcp.15144","article-title":"DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols","volume":"88","author":"Bozina","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.phrs.2026.108451_bib34","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1158\/1078-0432.CCR-10-2209","article-title":"Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer","volume":"17","author":"Deenen","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.phrs.2026.108451_bib35","first-page":"556","article-title":"DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients","volume":"19","author":"Del Re","year":"2019","journal-title":"Pharm. J."},{"issue":"7","key":"10.1016\/j.phrs.2026.108451_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16070956","article-title":"Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of DPYD Genotype-Guided Therapy with Fluoropyrimidines: An Observational Study","volume":"16","author":"Diaz-Villamarin","year":"2024","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.phrs.2026.108451_bib37","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41416-019-0423-8","article-title":"The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study","volume":"120","author":"Iachetta","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"15","key":"10.1016\/j.phrs.2026.108451_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25158503","article-title":"MIR27A Gene Polymorphism Modifies the Effect of Common DPYD Gene Variants on Severe Toxicity in Patients with Gastrointestinal Tumors Treated with Fluoropyrimidine-Based Anticancer Therapy","volume":"25","author":"Ikonnikova","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2026.108451_bib39","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4149\/neo_2009_04_303","article-title":"Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy","volume":"56","author":"Kleibl","year":"2009","journal-title":"Neoplasma"},{"key":"10.1016\/j.phrs.2026.108451_bib40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2018.07.009","article-title":"Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy","volume":"102","author":"Madi","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"20","key":"10.1016\/j.phrs.2026.108451_bib41","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1200\/JCO.2009.21.7943","article-title":"Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741","volume":"28","author":"McLeod","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.phrs.2026.108451_bib42","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2217\/pgs-2017-0118","article-title":"Use of exome sequencing to determine the full profile of genetic variants in the fluoropyrimidine pathway in colorectal cancer patients affected by severe toxicity","volume":"18","author":"Pellicer","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.phrs.2026.108451_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1248898","article-title":"Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece","volume":"14","author":"Ragia","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108451_bib44","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/bjc.2017.289","article-title":"Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients","volume":"117","author":"Ruzzo","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.phrs.2026.108451_bib45","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.31557\/APJCP.2019.20.10.3093","article-title":"Influence of DPYD*9A, DPYD*6 and GSTP1 ile105val Genetic Polymorphisms on Capecitabine and Oxaliplatin (CAPOX) Associated Toxicities in Colorectal Cancer (CRC) Patients","volume":"20","author":"Varma","year":"2019","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"5","key":"10.1016\/j.phrs.2026.108451_bib46","first-page":"741","article-title":"Polymorphisms of dihydropyrimidine dehydrogenase gene and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population","volume":"125","author":"Zhang","year":"2012","journal-title":"Chin. Med. J. (Engl. )"},{"issue":"11","key":"10.1016\/j.phrs.2026.108451_bib47","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1158\/1078-0432.CCR-11-0304","article-title":"Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients","volume":"17","author":"Afzal","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.phrs.2026.108451_bib48","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2217\/pme-2021-0047","article-title":"Investigation of DPYD, MTHFR and TYMS polymorphisms on 5-fluorouracil related toxicities in colorectal cancer","volume":"19","author":"Cevik","year":"2022","journal-title":"Per Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108451_bib49","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1186\/s12885-021-08745-0","article-title":"A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer","volume":"21","author":"Cordova-Delgado","year":"2021","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2026.108451_bib50","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/bcp.12631","article-title":"DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan","volume":"80","author":"Falvella","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.phrs.2026.108451_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004003","article-title":"Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients","volume":"3","author":"Gross","year":"2008","journal-title":"PLoS. One"},{"issue":"5","key":"10.1016\/j.phrs.2026.108451_bib52","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1120009X.2022.2125736","article-title":"DPYD and TYMS polymorphisms as predictors of 5 fluorouracil toxicity in colorectal cancer patients","volume":"35","author":"Khalij","year":"2023","journal-title":"J. Chemother."},{"issue":"3","key":"10.1016\/j.phrs.2026.108451_bib53","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1177\/147323001003800313","article-title":"Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients","volume":"38","author":"Kristensen","year":"2010","journal-title":"J. Int. Med. Res."},{"issue":"9","key":"10.1016\/j.phrs.2026.108451_bib54","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.31557\/APJCP.2022.23.9.3061","article-title":"Pharmacogenetic Study of the Dihydropyridine Dehydrogenase Gene in Jordanian Patients with Colorectal Cancer","volume":"23","author":"Almashagbah","year":"2022","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"1","key":"10.1016\/j.phrs.2026.108451_bib55","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00280-024-04722-z","article-title":"Influence of DPYD gene polymorphisms on 5-Fluorouracil toxicities in Thai colorectal cancer patients","volume":"95","author":"Atasilp","year":"2024","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108451_bib56","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s12957-020-02103-3","article-title":"Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms","volume":"18","author":"Deng","year":"2020","journal-title":"World J. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108451_bib57","doi-asserted-by":"crossref","first-page":"416","DOI":"10.21037\/jgo.2018.02.03","article-title":"Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines","volume":"9","author":"Khushman","year":"2018","journal-title":"J. Gastrointest. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108451_bib58","first-page":"e280","article-title":"The prevalence of DPYD*9A(c.85T>C) genotype and the genotype-phenotype correlation in patients with gastrointestinal malignancies treated with fluoropyrimidines: updated analysis","volume":"18","author":"Maharjan","year":"2019","journal-title":"Clin. Colorectal Cancer"},{"issue":"11","key":"10.1016\/j.phrs.2026.108451_bib59","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/1535-7163.MCT-06-0327","article-title":"Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance","volume":"5","author":"Morel","year":"2006","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.phrs.2026.108451_bib60","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.phrs.2026.108451_bib61","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1158\/0008-5472.CAN-13-2482","article-title":"Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity","volume":"74","author":"Offer","year":"2014","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.phrs.2026.108451_bib62","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1158\/0008-5472.CAN-12-3858","article-title":"Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity","volume":"73","author":"Offer","year":"2013","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2026.108451_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12020225","article-title":"Elevated risk of fluoropyrimidine-associated toxicity in European patients with DPYD genetic polymorphism: a systematic review and meta-analysis","volume":"12","author":"Kim","year":"2022","journal-title":"J. Pers. Med."},{"issue":"10","key":"10.1016\/j.phrs.2026.108451_bib64","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.7150\/ijbs.97686","article-title":"Clinical implementation of rare and novel DPYD variants for personalizing fluoropyrimidine treatment: challenges and opportunities","volume":"20","author":"De Mattia","year":"2024","journal-title":"Int. J. Biol. Sci."},{"issue":"45","key":"10.1016\/j.phrs.2026.108451_bib65","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1038\/s41388-025-03587-7","article-title":"Integration of germline pharmacogenomic burden to predict fluoropyrimidine-related toxicity - A secondary analysis of the PREPARE trial","volume":"44","author":"De Mattia","year":"2025","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.phrs.2026.108451_bib66","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40246-023-00546-9","article-title":"The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity","volume":"17","author":"De Mattia","year":"2023","journal-title":"Hum. Genom."},{"key":"10.1016\/j.phrs.2026.108451_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113644","article-title":"Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk","volume":"154","author":"De Mattia","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.phrs.2026.108451_bib68","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/bcp.15956","article-title":"Implementation of pre-emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?","volume":"91","author":"Peruzzi","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108451_bib69","unstructured":"Ensembl web site [Available from: https:\/\/www.ensembl.org\/index.html."},{"issue":"5","key":"10.1016\/j.phrs.2026.108451_bib70","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3892\/br.2025.2053","article-title":"Association between miRNA expression profiles and polymorphisms of dihydropyrimidine dehydrogenase drug-metabolizing gene in patients with colorectal cancer receiving 5-fluorouracil","volume":"23","author":"Phannasil","year":"2025","journal-title":"Biomed. Rep."},{"key":"10.1016\/j.phrs.2026.108451_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1516375","article-title":"Clinical implications of a gain-of-function genetic polymorphism in DPYD (rs4294451) in colorectal cancer patients treated with fluoropyrimidines","volume":"15","author":"De Mattia","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108451_bib72","doi-asserted-by":"crossref","DOI":"10.1097\/FPC.0000000000000611","article-title":"DPYD polymorphisms in Native populations from the Brazilian Amazon: the absence of the variants in currently recommended clinical genotyping panels","author":"Suarez-Kurtz","year":"2026","journal-title":"Pharm. Genom."},{"key":"10.1016\/j.phrs.2026.108451_bib73","article-title":"Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)","volume":"13","author":"Zhang","year":"2024","journal-title":"Elife"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182600366X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182600366X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:14:29Z","timestamp":1790799269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366182600366X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":73,"alternative-id":["S104366182600366X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108451","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DPYD c.85\u202fT\u202f>\u202fC, DPYD c.496\u202fA>G, and DPYD c.2194\u202fG>A and severe toxicity to fluoropyrimidines in PREPARE and Alpe-DPD trials. An original study and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108451","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108451"}}